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Abstract: Background: Treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) and
dietary phenylalanine and tyrosine restriction improves physical health and life expectancy in Tyrosinemia type 1
(TT1). However, neurocognitive outcome is suboptimal. This study aimed to investigate behavior problems and
health-related quality of life (HR-QoL) in NTBC-dietary-treated TT1 and to relate this to phenylalanine and tyrosine
concentrations.
Results: Thirty-one TT1 patients (19 males; mean age 13.9 ± 5.3 years) were included in this study. Emotional and
behavioral problems, as measured by the Achenbach System of Empirically Based Assessment, were present in
almost all domains. Attention and thought problems were particularly evident. HR-QoL was assessed by the TNO
AZL Children’s and Adults QoL questionnaires. Poorer HR-QoL as compared to reference populations was observed
for the domains: independent daily functioning, cognitive functioning and school performance, social contacts,
motor functioning, and vitality. Both internalizing and externalizing behavior problems were associated with low
phenylalanine (and associated lower tyrosine) concentrations during the first year of life. In contrast, high tyrosine
(and associated higher phenylalanine) concentrations during life and specifically the last year before testing were
associated with more internalizing behavior and/or HR-QoL problems.
Conclusions: TT1 patients showed several behavior problems and a lower HR-QoL. Associations with metabolic
control differed for different age periods. This suggests the need for continuous fine-tuning and monitoring of
dietary treatment to keep phenylalanine and tyrosine concentrations within target ranges in NTBC-treated TT1
patients.
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Background
Tyrosinemia type 1 (TT1; McKusick 276,700) is an in-
born error of tyrosine catabolism, caused by fumarylace-
toacetate hydrolase deficiency. This causes accumulation
of toxic metabolites which can result in liver failure and
hepatocellular carcinoma (HCC), renal tubular dysfunc-
tion and neurological porphyria-like crises [1]. Before the
1990s, dietary restriction of tyrosine and its precursor
phenylalanine was the only treatment to reduce the syn-
thesis of toxic metabolites, while not preventing liver com-
plications. Consequently, life expectancy was very poor
and liver transplantation was the only definitive treatment
option [2].
In 1992, 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclo-
hexanedione (NTBC) was introduced as a new treatment
[3]. NTBC blocks the tyrosine degradation pathway up-
stream from the primary defect, thereby preventing the
formation of toxic metabolites, but also leading to higher
tyrosine concentrations. Therefore, dietary restriction of
phenylalanine and tyrosine remains necessary. The use of
NTBC has undoubtedly improved outcome and life
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expectancy, preventing both hepatic and extrahepatic
problems [4].
However, recent studies suggest that the neurocogni-
tive outcome of NTBC-dietary-treated TT1 patients is
suboptimal [5–11]. Lower IQ values have been observed
along with impairment in various cognitive domains,
including executive functioning and social cognition.
These neurocognitive defects may underlie problems in
TT1 patients’ daily lives, such as school problems and at-
tention deficits. At present, knowledge of the cognitive-
behavioral phenotype associated with TT1 and its cause is
limited, although high tyrosine and low phenylalanine
concentrations may both be associated with brain dys-
function [5, 8, 12–14].
The present study aimed to investigate the emotional
and behavioral phenotype of TT1 patients and to look
for associations with biochemical parameters in a rela-
tively large patient group. First, we assessed the emotional
and behavioral problems and health-related quality of life
(HR-QoL) of TT1 patients. Second, we investigated the
relationship between these outcomes and plasma phenyl-
alanine and tyrosine concentrations.
Methods
Participants
In total, 31 TT1 patients (19 males) were included in
this cross-sectional study (mean age 13.9 ± 5.3 years)
(Table 1). Patients <six years and/or patients who
received liver transplantation were excluded. All patients
were treated with NTBC (typically at a dose of 1 mg/kg
body weight/day) and a phenylalanine-tyrosine-restricted
diet. Eleven patients had (or still) received phenylalanine
supplementation at the time of assessment because
phenylalanine concentrations were below the recom-
mended limit of 30 μmol/L [12]. Patients were included
from different centers in the UK, Belgium, and the
Netherlands between October 2012 and August 2018.
Plasma phenylalanine and tyrosine concentrations were
collected from patient records. The study was approved
by the Medical Ethical Committees of the participating
centers. All patients and/or parents gave informed con-
sent to participate in this study.
Instruments
To assess emotional and behavioral problems, the Achen-
bach System of Empirically Based Assessment (ASEBA)
questionnaires were used [15, 16]. The Child Behavior
Checklist (CBCL), suitable for age 6–12 years, was com-
pleted by parents. Adolescents (13–17 years) and adults
(≥18 years) filled out the Youth Self Report (YSR) or the
Adult Self Report (ASR). The CBCL, YSR, and ASR meas-
ure emotional and behavioral problems in seven different
dimensions: withdrawn/depressed, somatic complaints,
anxious/depressed, thought problems, attention problems,
rule-breaking behavior, and aggressive behavior. Addition-
ally, the CBCL and YSR assess social problems, whereas the
ASR assesses intrusive behavior. The sum of scores on di-
mensions withdrawn/depressed, somatic complaints, and
anxious/depressed forms the broadband scale ‘internalizing
problems’, while the broadband scale ‘externalizing prob-
lems’ is based on the rule-breaking, aggressive, and (in case
of the ASR) intrusive behavior dimensions [15, 16]. Fur-
thermore, six Diagnostic and Statistical Manual of Mental
Disorders (DSM) IV oriented scales were used. Different
scales were used for the CBCL and YSR (affective, anxiety,
somatic, attention deficit hyperactivity, oppositional, and
conduct problems), and the ASR (depressive, anxiety,
somatic, avoidant personality, attention deficit hyper-
activity, and antisocial personality problems). For all
ASEBA questionnaires, higher scores indicate more
problems in that domain.
To assess HR-QoL, the TNO AZL Children’s Quality
Of Life (TACQOL) questionnaire was used for children
aged < 16 years [17]. For analysis, this questionnaire was
divided into two parts: 1) for children aged 8–11 and 2)
for children aged 12–15 years. Both questionnaires in-
cluded 63 items and were filled out by the parents. For
children aged 8–11, the TACQOL questionnaire consisted
of seven different dimensions measuring physical func-
tioning/complaints (‘body’), motor functioning (‘motor’),
independent daily functioning (‘autonomy’), cognitive
functioning and school performances (‘cognition’), social
contacts with parents and peers (‘social’), occurrence of
positive moods (‘positive emotions’), and of negative
moods (‘negative emotions’). For children aged 12–15, the
dimensions autonomy and social were combined, measur-
ing interaction with peers (‘peers’). For participants aged
≥16 years, the TNO AZL Adult’s Quality Of Life (TAA-
QOL) questionnaire was used; this consisted of 45 items.
The TAAQOL included 12 different dimensions, i.e. gross
motor functioning (‘gross motor’), fine motor functioning
(‘fine motor’), cognitive functioning (‘cognition’), sleep
quality (‘sleep’), pain (‘pain’), social functioning (‘social’),
independent daily functioning (‘daily activities’), sexuality
(‘sex’), vitality (‘vitality’), positive moods (‘happiness’), de-
pressive moods (‘depressive’), and angry moods (‘anger’).
For all questionnaires, a higher score indicated a better
HR-QoL.
The HR-QoL data of TT1 patients was compared to a
Dutch reference population divided into 3 reference
groups of participants aged 8–11 years (N = 548), aged
12–15 (N = 393), and aged 16–30 years (N = 394).
Biochemical data
Patient data were collected from clinical records to investi-
gate differences within the TT1 group. Additionally, all
phenylalanine and tyrosine concentrations were retrieved
from the clinical patient records. Dried blood spot samples,
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when stated as such in the patient files, were excluded in
order to only include venous samples in our analysis. In
general, three to four venous samples were obtained every
year. Based on the existing literature on associations be-
tween metabolic control and behavioral outcomes in TT1
and phenylketonuria we focused on phenylalanine and
tyrosine levels during three periods in life: the first year
after birth, throughout lifetime (until assessment), and the
last year before assessment [5, 8, 13, 18, 19]. Since some
plasma phenylalanine concentrations < 30 μmol/L were un-
specified, imputation was used to allow inclusion of these
concentrations in analyses. For the imputation, median
phenylalanine concentrations < 30 μmol/L were calculated
using available data from other patients in whom the
plasma concentrations < 30 μmol/L were specified. Lifetime
concentrations were calculated as the median of yearly me-
dian phenylalanine and tyrosine levels.
Statistical analyses
For the analysis of emotional and behavioral problems,
raw ASEBA-scores were converted into T-scores to allow
comparison to the general population and between















Phe (μmol/L) Tyr (μmol/L) Phe (μmol/L) Tyr (μmol/L) Phe (μmol/L) Tyr (μmol/L)
1 6.6 < 2months No 10 195.5 43.5 512.5 44 518
2 7.3 > 6months Yes – – – – 29 344
3 7.9 > 6months No – – 42 389 41 521.5
4 8.1 Pre-symptomatic No 29.5 342.5 32.5 295 37 405
5 8.1 > 6months No – – 41 483.9 44 462
6 8.3 2–6 months Yes 28 257 19 376 18 401
7 8.8 Pre-symptomatic Yes 18 245 20 490 32 759.5
8 9.2 Pre-symptomatic Yes 26 281 21 457 39 514
9 9.7 2–6 months No 40 245 26 397 38 427
10 9.9 2–6 months Yes 16.5 155 27.8 370 45 572
11 10.3 Pre-symptomatic Yes 18 180 22 330 52 506
12 10.4 Pre-symptomatic Yes 18 280 31 370 60.5 615.5
13 10.6 Pre-symptomatic Yes – – 21 259 26 349
14 12.0 Pre-symptomatic No 26 448 – 518 30 477
15 12.1 Pre-symptomatic Yes 24 286 22 286 46.5 374
16 13.4 2–6 months No 43 300 30 407 – –
17 14.0 Pre-symptomatic No 55 538 47 668.3 52 959
18 15.1 < 2months Yes 61.5 372 24.5 542.5 67 746
19 15.4 Pre-symptomatic No 25 365.5 18 530.5 60 766
20 15.6 Pre-symptomatic No 39 643 42.5 628.5 45.5 700
21 16.0 2–6 months No 22.5 293 36.5 398.5 17 382
22 16.5 < 2months No 24 366.5 28 392 38 434
23 16.9 Pre-symptomatic No 41 361.5 46.3 713.5 64 866
24 17.7 2–6 months No 67 631 48 573 58 735.5
25 18.4 Pre-symptomatic No 22 351 10 509.5 – –
26 19.5 Pre-symptomatic No 41.5 663.5 20 625.3 – –
27 20.5 < 2months No – – – – 45.5 620.5
28a 22.5 Pre-symptomatic No – – – – 44 248
29b 23.0 2–6 months No 43 412.5 44.3 689 55 766
30c 23.3 > 6months Yes 60 43 42 306.8 45 280
31a 23.5 > 6months No 10 195.5 44.5 483 58 484
Patients that did not receive NTBC treatment directly after diagnosis are indicated with asterisks. aNTBC started approximately 1 month after diagnosis bNTBC
started < 1 year after diagnosis cNTBC started > 1 year after diagnosis
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different groups of TT1 patients. Descriptive analyses
were performed using pre-defined T-scores indicating
scores in the normal range (50–64), borderline range (65–
69) and clinical range (≥70) for all different subdomains of
the ASEBA questionnaires, and borderline range (60–63),
and clinical range (64–100) for internalizing problems and
externalizing problems [15, 16]. The borderline range
indicates that scores are not clearly deviant from norm
scores, but high enough to be of concern. Scores in the
clinical range indicate a deviation from norm scores, and
therefore possible clinical importance which may warrant
intervention. For the assessment of HR-QoL, TT1 patients
were compared with Dutch reference data using Mann-
Whitney U tests. Kruskal Wallis tests and/or Mann-
Whitney U tests were performed to analyze differences
within the TT1 group, comparing pre-symptomatically
versus symptomatically diagnosed patients, and symptom-
atically diagnosed patients diagnosed at different ages (< 2
months, 2–6months or > 6months of age [2]). Spearman
correlation tests were performed to study associations be-
tween behavior problems and HR-QoL, and between
behavior problems and HR-QoL-outcomes on the one
hand and plasma phenylalanine and tyrosine concentra-
tions on the other. The broadband ASEBA-scales were
excluded from these last correlational analyses since these
were calculated using the subdomains and therefore
significant results would be expected when subdomains
were statistically significant. All statistical analyses were
performed using IBM SPSS Statistics 22nd version and
p < 0.05 was considered statistically significant.
Results
Emotional and behavioral problems
Table 2 summarizes the findings of the ASEBA ques-
tionnaires. When considering internalizing problems,
47% of children, 22% of adolescents, and 14% of adults
with TT1 scored within the borderline or clinical range.
When considering externalizing problems, 54% of chil-
dren, 22% of adolescents and no adults scored within
the borderline or clinical range. TT1 children showed
problems in all domains, but especially with respect to
attention problems, with 53% being in clinical range.
Table 2 Results of the empirical and the DSM-IV oriented scales of the ASEBA questionnaires
Children (8–12) (N = 15, 9 males) Adolescents (13–17) (N = 9, 6 males) Adults (≥18) (N = 7, 4 males)
Borderline range (%) Clinical range (%) Borderline range (%) Clinical range (%) Borderline range (%) Clinical range (%)
ASEBA empirical scales
Withdrawn/ depressed 20 7 11 0 14 0
Somatic complaints 7 27 0 11 0 0
Anxious/ depressed 27 7 0 11 0 0
Social problems 7 27 11 11 – –
Thought problems 13 20 11 11 0 29
Attention problems 0 53 44 0 0 0
Rule-breaking behavior 13 27 0 11 0 14
Aggressive behavior 27 13 0 11 0 14
Intrusive behavior – – – – 0 0
Internalizing problems 7 40 11 11 14 0
Externalizing problems 7 47 11 11 0 0
ASEBA DSM-IV oriented scales
Affective problems 7 33 11 11 – –
Depressive problems – – – – 0 0
Anxiety problems 20 7 11 11 0 0
Somatic problems 13 27 0 11 29 0
Avoidant personality problems – – – – 0 14
Attention deficit hyperactivity
problems
13 40 22 0 14 0
Oppositional problems 13 7 0 22 – –
Conduct problems 27 20 0 11 – –
Antisocial personality
problems
– – – – 0 0
Internalizing problems are based on the withdrawn/depressed, somatic complaints, and anxious/depressed domains, and externalizing problems are based on
rule-breaking, aggressive, and (in case of the ASR) intrusive behavior domains
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Adolescents and adults especially showed thought and
attention problems, respectively. When investigating dif-
ferences between the different age groups using Kruskal-
Wallis analysis, children showed significantly more at-
tention problems than adults (p = 0.025). There were no
significant differences in behavior problems observed
between symptomatically and pre-symptomatically diag-
nosed patients.
Table 2 also shows the descriptive findings on the DSM-
IV oriented scales of the ASEBA. TT1 patients reported
problems on most scales, especially affective, somatic, at-
tention deficit hyperactivity, and conduct issues. Although
not statistically significant, scores within the borderline or
clinical range were generally observed more frequently in
children than in adolescents and adults.
Health-related quality of life
Figure 1a shows the results of the HR-QoL question-
naires of TT1 children compared to the Dutch reference
population. The TACQOL questionnaire for children
aged 8–11 showed a significantly lower HR-QoL for the
domains autonomy (p = 0.011), cognition (p = 0.029) and
social (p = 0.039) in TT1 patients. When comparing the
TACQOL scores for TT1 children aged 12–15 with the
corresponding reference population, a significantly lower
HR-QoL was observed on the domain body (p = 0.014)
(Fig. 1b). For both age groups (8–11 and 12–15), ana-
lyses of the TACQOL showed no significant differences
between pre-symptomatically and symptomatically diag-
nosed patients, and no differences between the different
times of diagnosis.
Figure 1c shows that adult TT1 patients (N = 9) re-
ported a significantly lower HR-QoL in the domains
gross motor (0.016), fine motor (p < 0.001), cognition
(p = 0.001), and vitality (p = 0.046). When comparing
pre-symptomatically (N = 3) and symptomatically (N = 6)
diagnosed patients, a significant difference was observed
on the domain vitality (p = 0.024), indicating a lower
HR-QoL in pre-symptomatically diagnosed patients. When
comparing groups based on age at diagnosis, no significant
differences were observed.
HR-QoL and emotional/behavioral problems were often
significantly correlated (see Additional files 1 and 2).
Phenylalanine and tyrosine associated to each other
As phenylalanine is a metabolic precursor of tyrosine, a
relationship between phenylalanine and tyrosine concen-
trations is expected. Phenylalanine and tyrosine concen-
trations during the first year of life were, indeed,
positively correlated (ρ = 0.532; p = 0.007), as were the
concentrations during the last year (ρ = 0.631; p < 0.001).
Lifetime concentrations showed a positive trend (ρ =
0.329; p = 0.094).
Associations of outcomes with first year plasma
phenylalanine and tyrosine concentrations
Significant negative correlations were observed between
first year phenylalanine concentrations and somatic com-
plaints (ρ = − 0.421; p = 0.040), social problems (ρ = − 0.457;
p = 0.043), thought problems (ρ = − 0.430; p = 0.040), and
attention problems (ρ = − 0.513; p = 0.010). Furthermore,
negative correlations were observed between first year tyro-
sine concentrations and social problems (ρ = − 0.608; p =
0.004), attention problems (ρ = − 0.598; p = 0.002), delin-
quent behavior (ρ = − 0.417; p = 0.043), and aggressive
behavior (ρ = − 0.438; p = 0.032). This indicates that low
phenylalanine (and the associated lower tyrosine) concen-
trations during the first year of life were associated with
both internalizing and externalizing behavior problems.
The DSM-IV oriented scales showed negative correla-
tions between first year tyrosine concentrations and
affective problems (ρ = − 0.449; p = 0.047), attention deficit
hyperactivity problems (ρ = − 0.493; p = 0.014), and con-
duct problems (ρ = − 0.667; p = 0.001).
Results for the HR-QoL in children, showed a positive
correlation between first year plasma phenylalanine con-
centrations and autonomy (ρ = 0.609; p = 0.016). In
adults, a negative correlation was observed between first
year phenylalanine concentrations and cognition (ρ = −
0.943; p = 0.005). Results of the correlation analyses are
also summarized in Additional file 3.
Associations of outcomes with lifetime plasma
phenylalanine and tyrosine concentrations
No significant correlations were observed between re-
sults on the ASEBA questionnaires and lifetime plasma
phenylalanine and tyrosine concentrations. Correlational
analyses with the HR-QoL questionnaires showed a posi-
tive correlation between lifetime phenylalanine concen-
trations and autonomy (ρ = 0.517; p = 0.034) in children,
indicating more autonomy with higher (normal rather
than low) phenylalanine concentrations. Furthermore,
negative correlations were observed between lifetime
phenylalanine concentrations and cognition (ρ = − 0.829;
p = 0.021) and social contacts (ρ = − 0.802; p = 0.030) in
patients aged > 16 years, indicating better HR-QoL with
lower phenylalanine concentrations (also see
Additional file 3).
Associations of outcomes with last year plasma
phenylalanine and tyrosine concentrations
A significant correlation was observed between the last
year phenylalanine concentrations and the score in the
withdrawn/depressed domain (ρ = 0.411; p = 0.030) indi-
cating more problems with higher phenylalanine con-
centrations. The last year tyrosine concentrations also
correlated with the withdrawn/depressed score (ρ = 0.492;
p = 0.008), indicating more problems with higher tyrosine
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concentrations. When investigating the DSM-oriented
ASEBA scales, higher phenylalanine concentrations corre-
lated with increased affective problems (ρ = 0.418; p =
0.047) and anxiety problems (ρ = 0.381; p = 0.045). These
findings indicate that higher (usually normal) phenylalan-
ine concentrations and the associated higher tyrosine con-
centrations are associated with more problems.
Results for the HR-QoL in children, showed a signifi-
cant negative correlation between the last year tyrosine
concentrations and positive emotions (ρ = − 0.505; p =
0.033), indicating more positive emotions with lower (to-
wards normal rather than high) tyrosine levels. In adult
patients, the last year phenylalanine concentrations
negatively correlated with the score in the social domain
(ρ = − 0.802; p = 0.030) (also see Additional file 3).
Discussion
In this study, we investigated emotional and behavioral
problems and HR-QoL in TT1 patients, and their rela-
tion to plasma phenylalanine and tyrosine concentra-
tions. The most important findings were that TT1
patients showed behavior problems and lower HR-QoL
on several domains compared to the Dutch reference
population used. Furthermore, several correlations were
observed between these neurocognitive impairments and
metabolic control. Most interestingly, correlations with
low plasma phenylalanine concentrations during the first
year(s) of life and high plasma tyrosine concentrations
later in life were observed.
With respect to behavior problems, in addition to the
attention problems that were identified previously [11],
our results showed TT1 patients treated with NTBC and
diet experienced a number of other behavior problems
including rule-breaking behavior, social problems, and
somatic complaints. On these domains, > 25% of the
children scored within the clinical range. Overall, both
internalizing and externalizing behavior problems were
found. As identified with the HR-QoL assessments, TT1
children described problems in cognitive functioning
and school performance, social contacts with parents
and peers and independent daily functioning. TT1 adults
had problems with gross and fine motor functioning,
cognition, and vitality.
Our results substantiate previous studies on neurocogni-
tive problems using other methods [5–8, 10, 11]. Although
chronic illness may directly affect HR-QoL [20], results on
the ASEBA and HR-QoL questionnaires were often associ-
ated, suggesting that chronic illness could also affect HR-
Fig. 1 HR-QoL of TT1 patients compared to controls. a. TACQOL for 8-11 year old children compared to controls (N=14 patients). b. TACQOL for
12-15 year old children compared to controls (N=5 patients). c. TAAQOL for patients ≥16 years old compared to controls (N=9 patients). Boxes
indicate 25-75 percentile, whiskers indicate min-max. * p<0.05, ** p<0.01
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QoL indirectly, through behavior problems. Thus, our
results stressed the importance of addressing both behav-
ioral problems and HR-QoL problems in daily patient care.
Furthermore, we investigated correlations with phenyl-
alanine and tyrosine concentrations as a possible cause
of the observed problems, which has not been studied in
such detail before. High phenylalanine and tyrosine
levels may have toxic effects on the brain, as shown in
disorders such as phenylketonuria and tyrosinemia type
2 [18, 21–23]. There is also evidence that low plasma
phenylalanine concentrations adversely affect the out-
comes in PKU [24] and TT1 [5, 12, 13]. It is important
to note that low plasma phenylalanine concentrations in
TT1 are likely to cause even lower phenylalanine con-
centrations in the brain because of competition with
tyrosine for influx across the blood-brain barrier. This
competitive inhibition has also been observed in PKU
where high phenylalanine concentrations inhibit the in-
flux of tyrosine [25]. Low cerebral concentrations of any
limiting essential amino acid may impair cerebral pro-
tein synthesis [26].
The results of this study indicate that, during the first
year of life, behavior problems correlate with low
phenylalanine rather than high tyrosine concentrations.
This changes later in life when, during last year before
testing, high tyrosine concentrations correlate with more
behavior problems (although they are associated with
higher phenylalanine levels). An attractive explanation
for this time dependency would be that while low
phenylalanine concentrations during the first year are
detrimental as a phenylalanine shortage impedes the
rapidly developing brain, at a later age the high tyrosine
concentrations may be more likely to have long term
chronic toxic effects. Further research is, however,
necessary to investigate this hypothesis. Moreover, the
relationship between amino acid levels and behavioral
outcomes may be non-linear, or only linear within cer-
tain ranges: both too low and too high amino acid levels
may be detrimental.
This study has a number of limitations, many of them
due to the rarity of TT1, affecting approximately 1:
100.000 newborns. Although inclusion of 31 patients
may be considered quite good, it is impossible to reach
high statistical power with such numbers, especially
since our patient sample was rather heterogeneous, vary-
ing in age, age at diagnosis, and symptoms at presenta-
tion. Moreover, patients were recruited from three
different countries, but for HR-QoL only Dutch refer-
ence data were available. We have, therefore, been cau-
tious of analyzing the influence of the aforementioned
variables on behavior/HR-QoL-outcomes. Furthermore,
the direct influence of NTBC could not be investigated.
Moreover, blood samples were taken under different
conditions (fasting/non-fasting) and at different time
points. Next to this, the effect of phenylalanine supple-
mentation and the different dosages, which could have
affected the phenylalanine and tyrosine concentrations,
could not be investigated in this study. Centers may dif-
fer in plasma analysis methods and number of samples
taken per patients.
Conclusion
To conclude, TT1 patients have more emotional and
behavioral problems, and a lower HR-QoL than healthy
individuals. The impairments in behavior and HR-QoL
were partly related to metabolic control, with low
phenylalanine and tyrosine levels in the first year of life
and high recent phenylalanine and tyrosine levels being
related to poorer outcomes. Whereas neonatal screening
and early treatment with NTBC have dramatically im-
proved physical health and life expectancy in TT1, the
data presented in this study underline the need to
optimize dietary treatment to improve emotional and
behavioral outcomes in this population.
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Additional file 1. Correlations between ASEBA questionnaires and QoL
questionnaires for children. Correlations between ASEBA questionnaires
and QoL questionnaires for children (N = 19). Bold and underlined results
are significant correlations. The QoL domain peers only consists of
children aged 12–15 years (N = 5).
Additional file 2. Correlations between ASEBA questionnaires and QoL
questionnaires for patients aged 16 and older. Correlations between
ASEBA questionnaires and QoL questionnaires for patients aged 16 and
older (N = 9). Bold and underlined results are significant correlations. For
patients 16–18 years old (N = 2), the ASEBA questionnaire did not
calculated the scales intrusive, depressed, avoidant and antisocial. The
domain sex could not be calculated for one of the patients due to
missing answers in the questionnaire.
Additional file 3. Summarized results of correlation analyses between
phenylalanine and tyrosine concentrations and neurocognitive outcome
scores. Summarized results of correlation analyses between phenylalanine
and tyrosine concentrations and neurocognitive outcome scores. Only
scales with significant correlations, with p-values < 0.05, are shown. ρ =
Spearman’s rho. For ASEBA, positive correlations indicate that higher
levels are related to poorer outcomes, whereas negative correlations
indicate that higher levels are related to better outcomes; for HR-QoL,
positive correlations indicate that higher levels are related to better out-
comes, whereas negative correlations indicate that higher levels are re-
lated to poorer outcomes.
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